Canakinumab is a recombinant human IgG1 kappa monoclonal antibody that is produced in murine Sp2/0-Ag14 cell line. This antibody binds to and neutralises human IL-1β preventing association with its receptor and subsequent inflammatory signaling cascade. The antibody neither has cross-reactivity with IL-1α nor with the Interleukin 1 receptor, type I (IL1R1). Canakinumab was developed by Novartis to treat rheumatoid arthritis. It received FDA approval in 2009 to treat cryopyrin-associated periodic syndromes (CAPS). Additionally, in 2016, Canakinumab received approval for the treatment of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulinemia D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF). This antibody is marketed under the trade name Ilaris®.
In PBS pH 7.5